Journal of Investigative Dermatology’s Post

Clexio Biosciences is pleased to announce that we have reached 50% enrollment in our CLE-400 Phase 2 proof-of-concept study, in subjects suffering from chronic pruritus associated with Notalgia Paresthetica.   The study is a randomized, double-blind, vehicle-controlled multi-center study, enrolling in the US, assessing the efficacy and safety of our CLE-400 topical gel.   Notalgia Paresthetica is a type of sensory neuropathy associated with chronic itch in the upper back. Patients’ quality of life, sleep, and mood can be negatively impacted by this condition. To-date, there are no approved treatments for this condition.   CLE-400 is a topical formulation containing a potent α2-adrenergic agonist, a non-opioid and non-steroid. CLE-400 is an investigational drug and is currently not approved for commercial distribution. For more information on CLE-400: https://lnkd.in/dQ-GJkwE #clexio #clinicaltrials #notalgiaparesthetica #itch #dermatology #neuropathy

Always exciting, the Spring #AAD meeting gives us opportunities network and to reconnect with friends and colleagues. As a forum for information exchange, the meeting is overwhelming with multiple simultaneous sessions and massive plenaries. For me, the most interesting sessions are the Late-Breaking Research Sessions. Seeing the effect of new pathways – Brunton’s tyrosine kinase inhibition for #HidradenitisSuppurativa, increases our understanding of the drivers of #HS. It is always exciting to see further development of new compounds – ESK-001, JNJ-77242113, delgocitinib, ritlecitinib, prepocitinib, povorcitinib, B-VEC, ICP-332, amlitelimab, lutikizumab, sonelokimab, nemolizumab, deuruxoltinib, benvitimod, SHR0302. Keep up the good work. #AAD2024 #dermatology #clinicalresearch #drugdevelopment

In recognition of #MelanomaAwarenessMonth, AMLo Biosciences are sharing (to US-only audience) a patient case study demonstrating the clinical utility of their #AMBLor technology that accurately stratifies early-stage, low-risk melanomas. https://lnkd.in/eehgYpVY AMBLor® testing service is provided by Avero Diagnostics as a physician-ordered, laboratory-developed test (LDT). The AMBLor test meets the U.S. Food and Drug Administration (FDA) definition and requirements for LDTs, but it has not been reviewed by the FDA. #dermatology #dermatopathology #histopathology #oncology #skincancer #cancerresearch #biomarkers

#Psoriasis affects 125 million people worldwide. It’s more than a skin condition—it can impact every aspect of life, bringing both physical discomfort and emotional strain. 🤝 This #WorldPsoriasisDay, we’re stepping up to support those living with plaque psoriasis, which accounts for 80-90% of cases. 📍 At Scinai Immunotherapeutics Ltd., we are dedicated to transforming psoriasis care. Our drug development program focuses on a targeted therapy specifically for mild to moderate plaque psoriasis. Leveraging single-domain antibodies (sdAbs), including our anti-IL-17A/F sdAb, we are advancing a locally administered biologic that combines high potency and convenience with a safer profile than current treatments. 👉 Join us in raising awareness and supporting those affected by psoriasis. Together, we can make a difference for millions. 🌐 Visit Scinai.com to learn more #InnovativeResearch #Healthcare #Biotechnology #Dermatology #WorldPsoriasisDay24

On this World Atopic Eczema Day, LEO Pharma shines a spotlight on atopic dermatitis (AD) - the most common form of eczema that affects millions of people across the globe. This chronic inflammatory skin condition not only causes physical discomfort with symptoms such as itch and pain, but also impacts the quality of life for patients, their families and caregivers. With AD often persisting into and sometimes beginning in adulthood, the condition results in a lifetime patient burden that is one of the largest among diseases worldwide. At LEO Pharma, we are driven to innovate to address such patient needs and strive to make a fundamental difference for those living with skin conditions. #LEOPharma #DermatologyBeyondTheSkin #AtopicEczemaDay

On this World Atopic Eczema Day, LEO Pharma shines a spotlight on atopic dermatitis (AD) - the most common form of eczema that affects millions of people across the globe. This chronic inflammatory skin condition not only causes physical discomfort with symptoms such as itch and pain, but also impacts the quality of life for patients, their families and caregivers. With AD often persisting into and sometimes beginning in adulthood, the condition results in a lifetime patient burden that is one of the largest among diseases worldwide. At LEO Pharma, we are driven to innovate to address such patient needs and strive to make a fundamental difference for those living with skin conditions. #LEOPharma #DermatologyBeyondTheSkin #AtopicEczemaDay

We recently we had the great pleasure of meeting with some of the world’s leading experts in the fields of #Dermatology and #AtopicDermatitis, to discuss clinical development plans for the lead candidate in our pipeline of disease-modifying #Therapies for chronic #Autoimmune and #InflammatoryDiseases. SYX-5219, which will advance into the clinic for the treatment of atopic dermatitis, targets a critical enzyme regulating cell #Metabolism called pyruvate kinase M2 (PKM2) – a novel therapeutic target with the potential to rebalance the #ImmuneSystem, normalize immune cell function and drive sustained disease remission.    As we finalise our development plans for this candidate, it’s vital that we collaborate with, and learn from, those who are expert in the field and those who are treating patients today. A huge thank you to everyone who shared their time, knowledge, insights and real-world experiences – invaluable to us in ensuring our #Science can continue to progress at pace for the benefit of patients.   Find out more about the latest progress within Sitryx’s proprietary pipeline: https://lnkd.in/eS8FGNRx

Check out the NACE Webcast: Atopic Dermatitis: Evaluation and Targeted Management. Atopic dermatitis (AD) is a chronic relapsing and remitting inflammatory skin disease that commonly presents in childhood. It is characterized primarily by scaly, pruritic, erythematous lesions located on flexural surfaces. The itch that accompanies AD has a significant impact on patients’ quality of life, with the most prominent impact being on sleep quality. Fortunately, a new understanding of its underlying pathophysiology has brought about a variety of effective treatment options for patients suffering from AD, from topical agents to biologics and oral Janus kinase (JAK) inhibitors. In this webcast, Mona Shahriari, MD, FAAD, will share her valuable insights on differential diagnosis, treatment goals, and individualizing treatment plans. Click here to start the course: https://bit.ly/3WdObsm #NACE #Dermatology #Webcast

Komal Nandure and I are excited to highlight our latest insights into the innovative advancements in psoriasis treatment!" Did you know that new treatments for psoriasis are changing the way we manage this challenging skin condition? Psoriasis affects millions of people worldwide, often leading to discomfort and a reduced quality of life. As a healthcare professional, staying updated on the latest treatment options is crucial to improving patient outcomes. In our latest clinical review, we explore the advancements in both topical and systemic treatments for psoriasis. From new topical formulations to cutting-edge biologics and JAK inhibitors, this article dives into the most recent innovations, their mechanisms, and their clinical benefits. #Psoriasis #Dermatology #Healthcare #ClinicalReview #InnovativeTreatments

Fuel your in vitro skin models with our unique human iPSC-derived sebocytes, and build robust and relevant tools for your research into skin disorders linked to hyper- and hypo-seborrhea, and for pharmacology, toxicology and drug discovery, including 3D skin reconstruction. Key highlights of our iPSC-derived sebocytes include: -Display the typical epithelial morphology of primary sebocytes with heterogeneity in cell size due to lipid accumulation. -Express the key sebocyte markers MUC1 (MUCIN 1) and KRT7 (KERATIN 7) -Exhibit functional response to testosterone and linoleic acid To find out why we are the only choice for iPSC-derived sebocytes, click here: https://lnkd.in/ew_jTiUK Looking to build human-relevant skin models for research or drug discovery? Let's have a conversation! operations@axolbio.com #iPSCs #StemCells #Sebocytes #Dermatology #SkinModels